Actively Recruiting
the Study of the Association Between the Gut Microbiota and Central Serous Chorioretinopathy
Led by Second Affiliated Hospital, School of Medicine, Zhejiang University · Updated on 2024-07-30
400
Participants Needed
1
Research Sites
109 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To investigate the potential association between gut microbiota and central serous chorioretinopathy (CSC), we have observed in our clinical practice that CSC patients often experience chronic gastrointestinal issues. This observation has led us to hypothesize that CSC may be associated with gut dysbiosis. The Bifidobacterium genus is widely recognized as a beneficial gut bacterium, and numerous well-established Bifidobacterium supplements are available on the market. To explore this possible connection, we will collect fecal samples from both CSC patients and healthy individuals. Using whole-metagenome shotgun sequencing, we will compare the gut microbiota compositions of the two groups to determine if significant differences exist. Additionally, we will randomly assign patients to two groups: one group will receive Bifidobacterium supplements for at least one month, while the other group will receive a placebo. We will then assess whether the group receiving the supplements experiences faster recovery and lower relapse rates compared to the placebo group.
CONDITIONS
Official Title
the Study of the Association Between the Gut Microbiota and Central Serous Chorioretinopathy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 to 60 years
- Diagnosis of acute central serous chorioretinopathy (CSC) with typical manifestations shown by FFA and ICGA
- Presence of subretinal fluid at the macular fovea
- Disease duration of 6 months or less
- Best Corrected Visual Acuity (BCVA) between 53 and 86 letters
- No significant systemic diseases
- Signed informed consent and ability to commit to follow-up
You will not qualify if you...
- Presence of significant systemic diseases
- Best Corrected Visual Acuity (BCVA) of 20/200 or worse
- Presence of choroidal or retinal atrophy in the macular fovea of the affected eye
- Presence of choroidal neovascularization, age-related macular degeneration, polypoidal choroidal vasculopathy, diabetic retinopathy, choroidal hemangioma, pigment epithelial detachment, or similar conditions in the affected eye
- High myopia in the affected eye
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
2 nd Affiliated Hospital, School of Medicine, Zhejiang University, China
Hanzhou, Zhejiang, China, 310000
Actively Recruiting
Research Team
W
Weixin Zheng, master
CONTACT
P
Panpan Ye, doctor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here